LivaNova PLC Company Profile (NASDAQ:LIVN)

LivaNova PLC trades on the NASDAQ under the ticker symbol "LIVN."

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, August, 9th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.82 by $0.19. The business earned $321.40 million during the quarter, compared to analyst estimates of $315.75 million. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. LivaNova PLC's revenue was up .1% compared to the same quarter last year. View LivaNova PLC's Earnings History.

LivaNova PLC is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for LivaNova PLC.

LivaNova PLC issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $3.10-3.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.10.

7 brokerages have issued 12 month price objectives for LivaNova PLC's stock. Their predictions range from $50.00 to $83.00. On average, they expect LivaNova PLC's share price to reach $71.50 in the next twelve months. View Analyst Ratings for LivaNova PLC.

Here are some recent quotes from research analysts about LivaNova PLC stock:

• 1. Canaccord Genuity analysts commented, "We come out of LIVN’s Investor Day with a better understanding of management’s approach to turning around this business and strategic plan for augmenting long-term, organic growth; however, we do not see a high-probability pathway to material organic growth acceleration near term. Moreover, while we remain very intrigued by the firm’s big shots on goal (i.e." (9/20/2017)
• 2. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
• 3. BTIG Research analysts commented, "Last week, while we were at our Snowbird conference, LIVN reported Q4 results and released initial FY17 guidance. Once again, we are lowering our estimates for LIVN. While shares are inexpensive, we do not see how it will grow in the future unless major M&A or R&D efforts take place, moving LIVN into new markets. Given most of LIVN’s markets are flat to declining, we would be inclined to wait for the company to show intentions to enter new markets before recommending shares. We don’t expect an inflection point on cardiac surgery anytime soon and while new iterations in Neuromod may pad growth in 2H17, we think the lower end of the 1-3% revenue growth guidance would be a good achievement. There remain considerable areas of opportunity on the synergy side, which should support EPS growth. With the first innings of physical integration behind them, we think the co. is in a better position to focus on more sizeable areas of savings such as purchasing/direct procurement. However, we think the lack of revenue growth is more important than synergies and we reiterate our Neutral rating." (3/10/2017)

Some companies that are related to LivaNova PLC include DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), Asante Solutions (PUMP), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO) and Orthofix International N.V. (OFIX).

LivaNova PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (10.42%), FMR LLC (9.84%), BlackRock Inc. (9.52%), State Street Corp (3.81%), Capital Research Global Investors (3.42%) and Koch Industries Inc. (2.92%). Company insiders that own LivaNova PLC stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova PLC.

LivaNova PLC's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Renaissance Technologies LLC, Employees Retirement System of Texas, OxFORD Asset Management LLP, FMR LLC, Janney Montgomery Scott LLC, JPMorgan Chase & Co. and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold LivaNova PLC stock in the last year include Alfred J Novak, Daniel Jeffrey Moore and Hugh M Morrison. View Insider Buying and Selling for LivaNova PLC.

LivaNova PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Koch Industries Inc., State Street Corp, HealthCor Management L.P., Franklin Resources Inc., Dimensional Fund Advisors LP, Redmile Group LLC and Janus Henderson Group PLC. View Insider Buying and Selling for LivaNova PLC.

Shares of LivaNova PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LivaNova PLC stock can currently be purchased for approximately $69.84.